206 related articles for article (PubMed ID: 37483873)
1.
Al-Ibraheem A; Scott AM
Nucl Med Mol Imaging; 2023 Aug; 57(4):168-171. PubMed ID: 37483873
[TBL] [Abstract][Full Text] [Related]
2. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
[TBL] [Abstract][Full Text] [Related]
3. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301
[TBL] [Abstract][Full Text] [Related]
4. New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC.
Rosar F; Maus S; Schaefer-Schuler A; Burgard C; Khreish F; Ezziddin S
Clin Nucl Med; 2023 May; 48(5):433-434. PubMed ID: 36758550
[TBL] [Abstract][Full Text] [Related]
5. Preclinical investigations and first-in-human application of
Müller C; Singh A; Umbricht CA; Kulkarni HR; Johnston K; Benešová M; Senftleben S; Müller D; Vermeulen C; Schibli R; Köster U; van der Meulen NP; Baum RP
EJNMMI Res; 2019 Jul; 9(1):68. PubMed ID: 31346796
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
7. Update on radioligand therapy with
Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
[TBL] [Abstract][Full Text] [Related]
8. Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint).
Myint K; Thein TM; Phyu TK; Maung W
Nucl Med Mol Imaging; 2019 Feb; 53(1):42-46. PubMed ID: 30828400
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and dosimetry of a single dose of albumin-binding ligand [
Kramer V; Fernández R; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Eppard E; Ceballos M; Meckel M; Benešová M; Umbricht CA; Kluge A; Schibli R; Zhernosekov K; Amaral H; Müller C
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):893-903. PubMed ID: 32949253
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
11. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
12. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Theranostics in Jordan.
Al-Ibraheem A; Mohamedkhair A
Nucl Med Mol Imaging; 2019 Feb; 53(1):7-10. PubMed ID: 30828393
[TBL] [Abstract][Full Text] [Related]
14.
Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
Front Oncol; 2022; 12():835956. PubMed ID: 35402274
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
16. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
17. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
18. Advances in
Ling SW; de Blois E; Hooijman E; van der Veldt A; Brabander T
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297601
[TBL] [Abstract][Full Text] [Related]
19. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
20. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
